• About AOP Orphan
    Slideshow Image

    About AOP Orphan

    Since its establishment 1996, AOP Orphan has focused on finding innovative solutions for Rare Diseases. Today AOP Orphan is a European pioneer in the field of Rare Diseases.

  • Patients & Relatives
    Slideshow Image

    Patients & Relatives

    Patients with rare disease often obtain little support. AOP Orphan saw potential in this need and is pleased to provide these patients with individualized therapies.


Hauptinhalt

A Pioneer in Rare Diseases

AOP Orphan was one of the first companies to enter the sector of Rare Diseases in Europe and continues to be a trailblazer in the field of Orphan Diseases to this day. As a specialist in Orphan Diseases, AOP Orphan researches, develops, produces, and distributes innovative solutions in the following therapeutic areas: hematology and oncology, cardiology and pulmonology, neurology and psychiatry, and metabolic diseases. Today AOP Orphan is active at an international level with an export ratio of about 70% and has become a leading company in its home market.

News

The Austrian pharmaceutical company AOP Orphan, which specialises in rare diseases and innovative therapies, will in future market the antiarrhythmic drug BRINAVESS®,...

The Austrian pharmaceutical company AOP Orphan is a European pioneer in the field of rare diseases. Industry expert Hans Peter Hasler (58) joined AOP Orphan’s...

AOP Orphan and Ferrer Internacional are expanding their long-standing partnership to include the marketing of the anti-psychotic drug Adasuve® (Staccato® Loxapine) in...